Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 10X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6ulixertinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2Vemurafenib 2Thalidomide 2Paclitaxel 2Nivolumab 2LY3023414 2Gemcitabine 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × diazepinomicin × Genitourinary × Clear all
NCT00338026 2008-07-15

A Phase I Study of ECO-4601 in Patients With Advanced Cancer

Thallion Pharmaceuticals

Phase 1 Completed
26 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Glioma, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡